Using microfluidic single cell culture to characterize cancer cell asymmetric division
Using microfluidic single cell culture to characterize cancer cell asymmetric division
批准号:
9237393
负责人:
Ronald J Buckanovich
金额:
$43.31万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-02-01 至 2017-08-25
关键词:
AcidosisAddressAlpha CellBiologic CharacteristicBiological ModelsCancer ModelCell Culture TechniquesCell Differentiation processCell SeparationCell divisionCellsClinicalComputer softwareDataData AnalysesDevicesDiseaseEnvironmental ImpactEventGene ExpressionGenesGenomic InstabilityGrowthGrowth FactorHumanHypoxiaIn VitroLinkMalignant NeoplasmsMalignant neoplasm of ovaryMetalsMicrofluidic MicrochipsMicrofluidicsModelingMolecularMolecular AnalysisMolecular ProfilingMonitorMothersMultipotent Stem CellsPathway interactionsPatientsPatternPhenotypePopulationProceduresQuantitative Reverse Transcriptase PCRRecurrent diseaseResistanceRetrievalSolid NeoplasmSpecimenStem cellsStressSystemTechnologyTestingTherapeuticTumor Initiatorsactionable mutationcancer cellcancer cell differentiationcancer stem cellcancer therapycell growthcell typechemotherapydaughter celldesigndifferential expressionhigh throughput analysisin vivointerpatient variabilityneoplastic cellnew technologynew therapeutic targetnovelnovel therapeuticsprogenitorprototypestem cell biologystem cell fatestem cell nichestem-like celltargeted treatmenttherapeutic targettooltranscriptome sequencingtumor initiation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Whether cancer follows a hierarchical (linear) or stochastic (random) model of differentiation has critical clinical
implications, yet remains highly controversial. The hierarchical model mirrors normal stem cell biology with
cancer stem-like cells (CSC) following an established pattern of asymmetric divisions to give rise to distinct
progeny. In this model only CSC can initiate recurrent disease. In the stochastic model, any given tumor cell
can asymmetrically divide to give rise to the other cells of the tumor and initiate recurrent disease. The key to
determining the pattern of differentiation is characterizing asymmetric division potential. However the
asymmetric division potential of primary human cancer cells has not been directly interrogated due to a lack of
technology. We hypothesize that cancer cells will follow a hierarchical differentiation pathway, but rare
stochastic dedifferentiation events occur allowing some cells to obtain a CSC state. We further hypothesize
that factors regulating the asymmetric division of cancer cells, both hierarchical and stochastic, will significantly
impact cancer growth and represent therapeutic targets. To address the technology deficiency, we propose
SA1: To develop a high-throughput single-cell microfluidic culture device with selective live-cell
retrieval. A highly parallel, compact, 1024 microwell design will allow efficient single cell capture, growth, and
characterization of asymmetric division of primary human cancer cells. Automated data analysis and selective
single-cell retrieval capacity will allow for high-throughput functional and molecular analysis of common and
rare events. In order to validate this important new technology we will use ovarian cancer as a model system.
We propose: SA2: To directly interrogate the asymmetric division potential of primary ovarian cancer
cells. Our preliminary data indicates that ovarian cancer follows a hierarchical differentiation model with rare
(~1/3000) putative stochastic ‘dedifferentiation’ events wherein a progenitor cell gives rise to putative CSC. We
will expand our studies of the asymmetric division potential to assess inter-patient variability and determine the
impact of environmental stresses on dedifferentiation rates. Critically, using selective cell retrieval we can
evaluate the biologic characteristics (chemotherapy resistance, tumor initiation capacity) of single cells derived
following an asymmetric division to confirm the biologic implications of differentiation and dedifferentiation
events. Finally, we propose SA3: To identify regulators of cancer cell differentiation and drivers of
dedifferentiation. In parallel to the functional studies in SA2, mother and daughter cells from asymmetric
divisions will be isolated and expression of distinct stem cell related genes assessed via single cell qRT-PCR.
Factors differentially expressed between mother and daughter cells will then be evaluated for their impact on
CSC growth and differentiation. To identify molecular drivers of the rare dedifferentiation events, we will
perform RNASeq comparing clones derived from hierarchical differentiation vs. stochastic dedifferentiation
events. Putative molecular drivers of dedifferentiation will then be confirmed both in vitro and in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10713051
-
项目类别:
-
资助金额:$23.49万
-
财政年份:2023
-
负责人:Ronald J Buckanovich
-
依托单位:
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy
-
批准号:10713054
-
项目类别:
-
资助金额:$37.2万
-
财政年份:2023
-
负责人:Ronald J Buckanovich
-
依托单位:
HCC Ovarian Cancer SPORE
-
批准号:10713050
-
项目类别:
-
资助金额:$216.38万
-
财政年份:2023
-
负责人:Ronald J Buckanovich
-
依托单位:
Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets
-
批准号:10750118
-
项目类别:
-
资助金额:$43.81万
-
财政年份:2023
-
负责人:Ronald J Buckanovich
-
依托单位:
Defining the impact of stromal aging on ovarian cancer initiation
-
批准号:10353485
-
项目类别:
-
资助金额:$46.64万
-
财政年份:2021
-
负责人:Ronald J Buckanovich
-
依托单位:
Defining the impact of stromal aging on ovarian cancer initiation
-
批准号:10491889
-
项目类别:
-
资助金额:$45.76万
-
财政年份:2021
-
负责人:Ronald J Buckanovich
-
依托单位:
Defining the impact of stromal aging on ovarian cancer initiation
-
批准号:10659225
-
项目类别:
-
资助金额:$45.81万
-
财政年份:2021
-
负责人:Ronald J Buckanovich
-
依托单位:
ALDH Inhibition as Modulator of Tumor Immunobiology
-
批准号:10392913
-
项目类别:
-
资助金额:$43.18万
-
财政年份:2020
-
负责人:Ronald J Buckanovich
-
依托单位:
ALDH Inhibition as Modulator of Tumor Immunobiology
-
批准号:10380368
-
项目类别:
-
资助金额:$6.04万
-
财政年份:2020
-
负责人:Ronald J Buckanovich
-
依托单位:
ALDH Inhibition as Modulator of Tumor Immunobiology
-
批准号:10524133
-
项目类别:
-
资助金额:$1.45万
-
财政年份:2020
-
负责人:Ronald J Buckanovich
-
依托单位:
ALDH Inhibition as Modulator of Tumor Immunobiology
-
批准号:10649413
-
项目类别:
-
资助金额:$42.77万
-
财政年份:2020
-
负责人:Ronald J Buckanovich
-
依托单位:
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy
-
批准号:10304184
-
项目类别:
-
资助金额:$33.67万
-
财政年份:2018
-
负责人:Ronald J Buckanovich
-
依托单位:
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy
-
批准号:10061581
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2018
-
负责人:Ronald J Buckanovich
-
依托单位:
The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy
-
批准号:10533768
-
项目类别:
-
资助金额:$33.67万
-
财政年份:2018
-
负责人:Ronald J Buckanovich
-
依托单位:
Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy
-
批准号:9288503
-
项目类别:
-
资助金额:$63.62万
-
财政年份:2017
-
负责人:Ronald J Buckanovich
-
依托单位:
Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma
-
批准号:10246576
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2017
-
负责人:Ronald J Buckanovich
-
依托单位:
Training in Cancer Therapeutics Research
-
批准号:9753159
-
项目类别:
-
资助金额:$8.82万
-
财政年份:2015
-
负责人:Ronald J Buckanovich
-
依托单位:
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics
-
批准号:9012021
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2012
-
负责人:Ronald J Buckanovich
-
依托单位:
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics
-
批准号:8619516
-
项目类别:
-
资助金额:$31.3万
-
财政年份:2012
-
负责人:Ronald J Buckanovich
-
依托单位:
Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics
-
批准号:8434838
-
项目类别:
-
资助金额:$30.33万
-
财政年份:2012
-
负责人:Ronald J Buckanovich
-
依托单位:
海外基金